Tag: coherus biosciences

March 13, 2019

An Investor’s Overview to Biosimilars

Biosimilars are growing in popularity in both Canada and the US. Here is an overview of the biosimilars market for...
January 25, 2019

Coherus BioSciences Announces Global Settlement with AbbVie

Coherus BioSciences (Nasdaq:CHRS), a commercial biosimilar company, announced it has executed settlement agreements with AbbVie that grant Coherus global, non-exclusive...
January 10, 2017

Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis

Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA)...
October 7, 2016

Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License Application for CHS-1701

Coherus BioSciences, a leading pure-play, global biosimilar company with late-stage clinical products, today announced that the U.S. FDA has accepted...
June 28, 2016

Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting Multiple Sclerosis

Six Month Study Demonstrates Significant Reduction in Contrast-Enhancing Lesions Meeting Primary Endpoint Safety and Tolerability Support Differentiated Product Profile REDWOOD...
May 17, 2016

Coherus BioSciences Provides Update on ‘135 IPR

REDWOOD CITY, Calif., May 17, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with...
May 4, 2016

Coherus BioSciences to Present at Bank of America Merrill Lynch Health Care Conference on May 11

May 04, 2016 09:30 ET | Source:Coherus BioSciences, Inc. REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) — Coherus BioSciences,...